ClinicalTrials.gg
Enrolling by invitationNCT03576573Updated Nov 14, 2023

Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular Components

An observational study in Joint Disease, sponsored by MicroPort Orthopedics Inc.. Enrolling by invitation at 1 site in Germany. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-11-14.

Sponsored by MicroPort Orthopedics Inc. (part of MicroPort Scientific Corporation) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
143
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Joint Diseases by MicroPort Scientific Corporation — 5 open to participants now, 13 under way, none of them phase 3. Joint Diseases · MicroPort Scientific Corporation.

Planned enrollment
5th of 20
143 · median 69
Started
2019
with 2 others
Observational
20 of 21
5 open now
Primary completion
2032-12
later than 8 of 12 live
Registered
14th of 21
by date

Among the 21 studies in Joint Diseases by MicroPort Scientific Corporation, this one is the 5th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2019, is one of 20 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 14th registered.

Joint Diseases

386 studies on the registry are indexed under Joint Diseases; 64 are open to participants now.

Browse Joint Diseases studies →

Open to participants now

5 of the 21 studies in Joint Diseases by MicroPort Scientific Corporation are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 44 Joint Diseases studies recruiting now, 24 (55%) set no upper age limit and 11 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Joint Diseases by MicroPort Scientific Corporation, or all of them as a file.
02

Study summary

MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in Europe. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.

03

Conditions studied

  • Joint Disease

Keywords

  • Osteoarthritis
  • Avascular necrosis
  • Ankylosis
  • Protrusio acetabuli
  • Painful hip dysplasia
  • Rheumatoid arthritis
  • Correction of functional deformity
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology Femoral Stems and PROCOTYL® C Acetabular Components

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in the study, subjects must meet all of the following criteria:

  • Has previously undergone primary Total Hip Arthroscopy for any of the following:
  • Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;
  • Inflammatory degenerative joint disease such as rheumatoid arthritis;
  • Correction of functional deformity
  • Subject was implanted with the specified combination of components, namely, any MicroPort Orthopedics or Wright Medical Technology femoral stem and PROCOTYL C Acetabular Components
  • Subject is willing and able to complete required study visits or assessments

Previously implanted bilateral subjects can have both THAs (Total Hip Arthroscopy) enrolled in the study provided:

  1. the specified combination of components were implanted in both,
  2. all other aspects of the Inclusion/Exclusion Criteria are satisfied,
  3. enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and
  4. the subject agrees to a second document specific to the second THA. Prospective enrolment of a previously unimplanted hip is not permitted in this study.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded if they meet any of the following criteria:

  • Subject was skeletally immature (less than 21 years of age) at time of implantation
  • Subject has a non-MicroPort or non-Wright Medical Technology component implanted (femoral heads, acetabular shells, acetabular liners) in the enrolled Total Hip Arthroscopy
  • Subject is currently enrolled in another clinical investigation which could affect the endpoints of this protocol
  • Subject is unwilling or unable to sign the document
  • Subject has documented substance abuse issues
  • Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
  • Subject is currently incarcerated or has impending incarceration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
143 participants (estimated)
Patient registry
No

Groups and cohorts

  • Primary Total Hip Arthroplasty

    Single arm study of subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology femoral stems and PROCOTYL® C Acetabular Components

    Device: PROCOTYL® C

Interventions

  • DevicePROCOTYL® C

    Hip Arthroplasty

    Also known as: Primary Total Hip Device

06

What researchers measure

Primary outcomes

  1. Component Survivorship

    The primary endpoint is to evaluate component survivorship of the PROCOTYL® C Acetabular Components out to 10 years follow-up. Percentage of hips survived with no revision or replacement at 10-year.

    Time frame: 10 years post-operative

Secondary outcomes

  1. To determine the cumulative incidence of component revision at specified intervals out to 10 years follow-up;

    Percentage of hips that were revised or replaced at each of the intervals namely for Early (2-5 years), midterm (5-7 Year), and long-term (10-year) evaluation.

    Time frame: 2-5 years, 5-7 years, and 10 years

  2. To characterize functional scores, as assessed by Oxford Hip.

    The study will be reporting the final Oxford Hip score, which is a summary over 12 items. Each of these items is 5-level Likert scale such as from 'not at all' to 'totally'.

    Time frame: 2-5 years, 5-7 years, and 10 years

  3. To characterize functional scores, as assessed by EQ-5D-3L scores.

    EQ-5D-3L data will be summarized over 5 domains, namely, mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain has 3 levels: no problems, some problems, and extreme problems.

    Time frame: 2-5 years, 5-7 years, and 10 years

07

Study locations

1 site
  • Elbe Kliniken Buxtehude
    Buxtehude, 21614, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2019 (actual). Primary completion is estimated for Dec 2032, 165 months after the start.

Of 58 observational studies under Joint Diseases, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 153. This study's planned 165 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2018
First posted
Jul 3, 2018
StartActual
Mar 27, 2019
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2032
Last update
Nov 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03576573
Responsible party
Sponsor
First posted
Jul 3, 2018
Start date
Mar 27, 2019
Primary completion
Dec 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Nov 14, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion